In 2013, the FDA approved Second Sight Medical’s Argus II, a retinal prosthesis that provides artificial vision by converting images into electrical pulses that can be read by the brain. More than 350 people worldwide received the implant over the last decade, but according to a recent FierceBiotech article, the company has left the users high and dry. Due to financial issues, Second Sight began phasing the Argus II out in 2019. This month, the process was expedited amid the company’s plan to pivot and merge with Nano Precision Medical, a drug delivery implant maker.
Second Sight Leaves Patients with Obsolete Implants
As the company prepares to merge and pivot, 350+ people with Argus II implants will soon be left in the dark.
Feb 21, 2022
Recommended
Recommended
Recommended
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
